Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of Lianhua Yuping Granules for common cold with qi deficiency syndrome
CTR20252757Phase 2Active
- Sponsor
- Yiling Pharmaceutical
- Start
- Aug 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Lianhua Yuping granules in nasopharyngitis, sponsored by Yiling Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
Lianhua Yuping granules
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on CTR20252757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252757.